mipafox: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9738 |
| CHEBI ID | 82142 |
| SCHEMBL ID | 119253 |
| MeSH ID | M0046640 |
| Synonym |
|---|
| fluorobisisopropylaminophosphine oxide |
| phosphorodiamidic fluoride, n,n'-bis(1-methylethyl)- |
| brn 1705911 |
| n,n'-diisopropyl-diamido-phosphorsaeure-fluorid [german] |
| mipafox [iso] |
| bis(isopropylamido)fluorophosphate |
| phosphorodiamidic fluoride, n,n'-diisopropyl- |
| hsdb 1585 |
| bisisopropylaminofluorophosphine oxide |
| caswell no. 356b |
| n,n'-diisopropil-fosforodiammido-fluoruro [italian] |
| n,n'-diisopropyl-diamido-fosforzuur-fluoride [dutch] |
| nsc 8924 |
| einecs 206-742-3 |
| epa pesticide chemical code 356300 |
| fluorure de n,n'-diisopropyle phosphorodiamide [french] |
| fluoro[bis(isopropylamino)]phosphine oxide |
| n,n'-diisopropil-fosforodiammido-fluoruro |
| phosphorodiamidic fluoride,n'-diisopropyl- |
| n,n'-diisopropyl-diamido-phosphorsaeure-fluorid |
| n,n'-diisopropylphosphorodiamidic fluoride |
| peston xv |
| isopestox |
| pestox xv |
| di(isopropylamido)phosphoryl fluoride |
| n,n'-diisopropyldiamidophosphoryl fluoride |
| n,n'-diisopropyl-diamido-fosforzuur-fluoride |
| wln: 1y1&mpo&fmy1&1 |
| phosphorodiamidic fluoride,n'-bis(1-methylethyl)- |
| bis(monoisopropylamino)fluorophosphate |
| 371-86-8 |
| pestox 15 |
| bis(monoisopropylamino)fluorophosphine oxide |
| phosphorodi(isopropylamidic) fluoride |
| fluorure de n,n'-diisopropyle phosphorodiamide |
| mipafox |
| nsc-8924 |
| bis(isopropylamido) fluorophosphate |
| phosphine oxide, fluorobis(isopropylamino)- |
| nsc8924 |
| n,n'-bis(1-methylethyl)phosphorodiamidic fluoride |
| n-[fluoro-(propan-2-ylamino)phosphoryl]propan-2-amine |
| C19008 |
| 4-04-00-00536 (beilstein handbook reference) |
| 24mjp5h3yn , |
| unii-24mjp5h3yn |
| AKOS017258617 |
| mipafox [mi] |
| mipafox [hsdb] |
| SCHEMBL119253 |
| STL388019 |
| n,n'-dipropan-2-ylphosphorodiamidic fluoride |
| CHEBI:82142 |
| UOSHUBFBCPGQAY-UHFFFAOYSA-N |
| n,n'- di-isopropylphosphorodiamidic fluoride |
| un 2783 (salt/mix) |
| fluoro(bis(isopropylamino))phosphine oxide |
| DTXSID5042160 |
| mfcd00801119 |
| Q26841312 |
| FT-0775089 |
| n,n'-diisopropyl-phosphorodiamidic fluoride, mipafox |
| bis[(propan-2-yl)amino]phosphinoyl fluoride |
| EN300-266699 |
| Z1681338465 |
Mipafox is a neuropathic organophosphate.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Mipafox is a neuropathic organophospate." | ( In vitro protection of red blood cell acetylcholinesterase by metoclopramide from inhibition by organophosphates (paraoxon and mipafox). Arafat, K; Camasamudram, V; Hasan, MY; Kosanovic, M; Petroianu, G; Saleh, A, ) | 1.06 |
| "Mipafox is a neuropathic organophosphate." | ( In vitro protection of plasma cholinesterases by metoclopramide from inhibition by mipafox. Arafat, K; Kühn, F; Missler, A; Petroianu, G; Zuleger, K, ) | 1.08 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Mipafox caused an increase in prejunctional (end-plate potential) jitter at 28 days after dosing in both muscles." | ( A comparison of the electrophysiological effects of two organophosphates, mipafox and ecothiopate, on mouse limb muscles. Blain, PG; de Blaquière, GE; Kelly, SS; Williams, FM, 1998) | 1.25 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Hens treated with Mipafox (10 mg/kg, sc), sarin (50 micrograms/kg, sc) or parathion (1 mg/kg, sc) daily for 10 days exhibited severe, moderate and no ataxia respectively on 14th day after the start of exposure. " | ( A comparative study of delayed neurotoxicity in hens following repeated administration of organophosphorus compounds. Das Gupta, S; Husain, K; Pant, SC; Raza, SK; Singh, R, 1995) | 0.63 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " BaP was the most toxic of all PAHs tested, and anthracene failed to produce a toxic response at any concentration tested." | ( Neurotoxicity of polycyclic aromatic hydrocarbons and simple chemical mixtures. Donnelly, KC; Mumtaz, MM; Tang, Y; Tiffany-Castiglioni, E, 2003) | 0.32 |
| " The main toxic mechanism of OPs is the inhibition of acetylcholinesterase (AChE); however, the delayed neuropathy induced by OPs (OPIDN) is mediated by other mechanisms such as the irreversible inhibition of 70% of NTE activity (neuropathy target esterase) that leads to axonal degeneration." | ( The Antidiabetic Drug Liraglutide Minimizes the Non-Cholinergic Neurotoxicity of the Pesticide Mipafox in SH-SY5Y Cells. Dos Santos, AC; Dos Santos, NAG; Emerick, GL; Fernandes, LS, 2019) | 0.73 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The comparison of the results between the intact cells and the lysed cells suggests that the plasma membrane could act as a barrier that reduced the bioavailability of mipafox to PVases." | ( Hydrolyzing activities of phenyl valerate sensitive to organophosphorus compounds paraoxon and mipafox in human neuroblastoma SH-SY5Y cells. Del Río, E; Estévez, J; González-González, M; Sogorb, MA; Vilanova, E, 2018) | 0.89 |
Phenylmethylsulfonyl fluoride (PMSF) is a protease and esterase inhibitor. It causes protection, or potentiation/"promotion," of organophosphorus delayed neuropathy (OPIDN), depending on whether it is dosed before or after mipafox.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In rats, these lesions were well developed in only the highest dosage group and confined to the rostral level of the fasciculus gracilis in the medulla oblongata." | ( Comparative dose-response studies of organophosphorus ester-induced delayed neuropathy in rats and hens administered mipafox. Dyer, KR; Ehrich, M; Jortner, BS; Shell, LG, 1992) | 0.49 |
| " Only hens dosed at the maximum dose in both extremities presented alterations in motility (Grade 1 or 2 on a 0-8 scale), suggesting no significant central nervous system alterations." | ( Local application of neuropathic organophosphorus compounds to hen sciatic nerve: inhibition of neuropathy target esterase and peripheral neurological impairments. Barril, J; Carrera, V; Mauricio, M; Pellín, M; Vilanova, E, 1992) | 0.28 |
| " These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14-21 days post-exposure." | ( The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats. Lyerly, D; Padilla, S; Veronesi, B, 1986) | 0.51 |
| " Serum testosterone levels also measured 15 days after dosing were not different from those of a control group." | ( Neurotoxic esterase in rooster testis. Becker, CE; Lotti, M; Spear, RC; Wei, ET, 1985) | 0.27 |
| " Conversely, another group of rats, pretreated with Mipafox, was dosed with PMSF when NTE inhibition was 90." | ( Phenylmethylsulfonyl fluoride protects rats from Mipafox-induced delayed neuropathy. Padilla, S; Veronesi, B, 1985) | 0.77 |
| "5 mg/kg, sc), an inhibitor of acetylcholinesterase (AChE) activity, exhibited the symptoms of cholinergic hyperactivity between Days 3 and 5 similar to those observed 15 min after a single acute dosage (1." | ( Mechanisms involved in the development of tolerance to DFP toxicity. Dettbarn, WD; Gupta, RC; Patterson, GT, 1985) | 0.27 |
| " At intervals up to 77 days after dosing animals were killed and muscle action potentials and endplate potentials were recorded intracellularly in mouse phrenic-nerve/hemidiaphragm preparations." | ( Electrophysiological and biochemical effects following single doses of organophosphates in the mouse. Blain, PG; Kelly, SS; Mutch, E; Williams, FM, 1994) | 0.29 |
| " At 7 and 28 days after dosing action potentials and evoked endplate potentials, produced by stimulating the phrenic nerve at 30 Hz, were recorded in diaphragm muscle." | ( Effects of multiple doses of organophosphates on evoked potentials in mouse diaphragm. Blain, PG; de Blaquière, GE; Kelly, SS; Williams, FM, 1997) | 0.3 |
| " However, if PMSF is dosed after a low non-neuropathic dose of a neuropathic OP, its neurotoxicity is 'promoted', causing severe neuropathy." | ( Discrimination of carboxylesterases of chicken neural tissue by inhibition with a neuropathic, non-neuropathic organophosphorus compounds and neuropathy promoter. Barril, J; Céspedes, MV; Escudero, MA; Sogorb, MA; Vicedo, JL; Vilanova, E, 1997) | 0.3 |
| " Mipafox caused an increase in prejunctional (end-plate potential) jitter at 28 days after dosing in both muscles." | ( A comparison of the electrophysiological effects of two organophosphates, mipafox and ecothiopate, on mouse limb muscles. Blain, PG; de Blaquière, GE; Kelly, SS; Williams, FM, 1998) | 1.44 |
| " The biosensor was used to establish correlations of NTE inhibitions in blood with that in lymphocytes and brain after dosing hens with a neuropathic OP." | ( Biosensor assay of neuropathy target esterase in whole blood as a new approach to OPIDN risk assessment: review of progress. Eremenko, AV; Kurochkin, IN; Makhaeva, GF; Malygin, VV; Richardson, RJ; Sigolaeva, LV; Sokolovskaya, LG; Strakhova, NN, 2007) | 0.34 |
| " This kind of interaction among esterase inhibitors should be considered to study the potentiation/promotion phenomenon, which is observed when some esterase inhibitors enhance the severity of the OP induced neuropathy if they are dosed after a non neuropathic low dose of a neuropathy inducer." | ( Interactions of neuropathy inducers and potentiators/promoters with soluble esterases. Estévez, J; Mangas, I; Sogorb, MÁ; Vilanova, E, 2013) | 0.39 |
| "Phenylmethylsulfonyl fluoride (PMSF) is a protease and esterase inhibitor that causes protection, or potentiation/"promotion," of organophosphorus delayed neuropathy (OPIDN), depending on whether it is dosed before or after an inducer of delayed neuropathy, such as mipafox." | ( Kinetic interactions of a neuropathy potentiator (phenylmethylsulfonyl fluoride) with the neuropathy target esterase and other membrane bound esterases. Estévez, J; Mangas, I; Vilanova, E, 2014) | 0.58 |
| Class | Description |
|---|---|
| phosphoramide | A compound in which one or more of the OH groups of phosphoric acid have been replaced with an amino or substituted amino group. The term is commonly confined to the phosphoric triamides, P(=O)(NR2)3, since replacement of one or two OH groups produces phosphoramidic acids: P(=O)(OH)(NR2)2 , P(=O)(OH)2(NR2). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 27 (26.73) | 18.7374 |
| 1990's | 39 (38.61) | 18.2507 |
| 2000's | 21 (20.79) | 29.6817 |
| 2010's | 14 (13.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.30) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (0.93%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 106 (99.07%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||